Stoke Therapeutics (STOK) Fundamental Analysis: Revenue, Earnings & Valuation

6.47 / 10

Outperform

Fundamentally, STOK rates Outperform with a 6.5/10 score. Key strengths include high inventory turnover (106.6) and a 100% gross profit margin. Asset‑MV, Revenue‑MV, Profit‑MV and Cash‑MV metrics sit in upper quartiles, indicating favorable valuation and cash position.

Analysis Checks(10/10)

Revenue-MV

Value-5.08

Score3/3

Weight14.80%

1M Return9.51%

Inventory turnover ratio

Value106.57

Score3/3

Weight9.04%

1M Return6.65%

Gross profit margin (%)

Value100.00

Score2/3

Weight1.92%

1M Return1.67%

Profit-MV

Value0.68

Score3/3

Weight16.67%

1M Return9.40%

Income tax / Total profit (%)

Value22.35

Score2/3

Weight1.07%

1M Return0.98%

Current assets turnover ratio

Value0.69

Score2/3

Weight1.95%

1M Return1.91%

Fixed assets turnover ratio

Value25.44

Score2/3

Weight0.01%

1M Return0.01%

Cost of sales ratio (%)

Value57.03

Score3/3

Weight4.49%

1M Return4.08%

Asset-MV

Value-0.55

Score2/3

Weight20.76%

1M Return13.10%

Cash-MV

Value0.03

Score3/3

Weight29.30%

1M Return15.07%

Is STOK fundamentally strong?

STOK scores 6.47/10 on fundamentals and holds a Discounted valuation at present. Backed by its -2.37% ROE, -3.73% net margin, -282.22 P/E ratio, 5.51 P/B ratio, and 92.73% earnings growth, these metrics solidify its Outperform investment rating.